Our Expertise
Since the founding of Atessia, our commitment to excellence and expertise in the pharmaceutical industry have established us as a key player in regulatory affairs consulting. Following the integration of AnticipSanté, now rebranded as 'Atessia Vigilances', we are strengthening our positioning and expanding our expertise to provide our clients with increasingly tailored solutions for pharmaceutical and healthcare vigilance challenges. This strategic merger is fully aligned with the Life Science constellation of Atessia & Co, a network that brings together complementary talents and expertise to support healthcare stakeholders in addressing their regulatory and operational challenges on a global scale.
Dr. géraldine baudot-visser
Doctor of Pharmacy
MSc in the Development and Control of Natural and Synthetic Drugs (Paris)
Géraldine began her career in a research and development parent pharmaceutical company (Negma-Lerads / Steba Biotech) as a Technico-Regulatory Pharmacist coordinating CMC projects to develop chemical, semi-synthetic, and biotechnological molecules and associated medical devices for completion of the pre-clinical and clinical phases (up to Phase 3) for the Europe (IMPD), US (IND), and Canada (CTA) zones.
She then turned her focus to post-approval as Regulatory Affairs Manager of a post-MA product portfolio at BMS – UPSA in liaison with drug manufacturers.
She subsequently developed her techno-regulatory skills for ten years as a Regulatory and Pharmaceutical Affairs Consultant in the pharmaceutical unit of a renowned firm (A.R.C. Pharma).
She was responsible for regulatory and pharmaceutical advice, initial Marketing Authorization (Modules 1 and 3) and/or variation applications, MA renewals, the associated registration strategy, due diligence on product sales, and managing pharmaceutical projects, especially in the context of site transfers. She also supported clients in opening and operating pharmaceutical establishments with exploitant status.
She has been able to develop her network of experts and speakers by launching annual two-day seminars on topical regulatory and pharmaceutical subjects.
Géraldine aimed to establish her own consulting and expertise firm in regulatory and pharmaceutical affairs, called ‘ATESSIA.’ The goal is to introduce a fresh, customer-centric approach to meet the specific expertise needs of healthcare industry professionals. In line with this commitment to excellence, Atessia has pursued ISO 9001 certification, embodying a continuous improvement initiative in its services.
Atessia & Co
Then, in 2021, in order to complete the service offering, she developed a new entity, ‘AMARYLYS,’ which is positioned to delegate consultants within the healthcare industries in the same fields of activity.
In 2025, Atessia took another significant step by integrating Atessia Vigilances into its portfolio. This new division builds on the expertise of AnticipSanté, now rebranded as Atessia Vigilances, further enhancing the company’s commitment to providing comprehensive solutions for vigilance and regulatory compliance. With a team of experts specializing in pharmacovigilance, cosmetovigilance, materiovigilance, and nutrivigilance, Atessia Vigilances offers advanced services that help healthcare professionals navigate complex regulatory landscapes, detect safety signals, and ensure product compliance across Europe and beyond. Through this strategic move, Atessia continues to strengthen its position as a leader in providing tailored, high-quality support to the healthcare industry.
